Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 77.50
Bid: 70.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 15.00 (21.429%)
Open: 77.50
High: 77.50
Low: 77.50
Prev. Close: 77.50
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

22 Apr 2020 07:00

RNS Number : 4131K
Biome Technologies PLC
22 April 2020
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR")

 

22 April 2020

 

 

Biome Technologies plc

 

("Biome", "the Company" or "the Group")

 

Trading Update

 

 

 

The Annual General Meeting ("AGM") of Biome Technologies, a leading bioplastics and radio frequency technology business, was due to be held today. Whilst the AGM has been delayed due to Covid-19, the Board is pleased to announce the Company's customary trading update for the three months ended 31 March 2020.

 

Group revenues achieved for the first three months of the year were £1.3m (Q1 2019: £2.1m), reflecting a very strong revenue performance from the Bioplastics division and subdued demand in the Stanelco RF division.

 

The impact of Covid-19 on Biome during the first quarter of 2020 was limited, with trading in the quarter being in line with management's expectations at the time of the Group's trading update on 30 January 2020. The Group continues its manufacturing and development operations with the upmost consideration for the safety of its staff and in conformance with Government advice.

 

The Group remained debt free as at 31 March 2020 and had cash of £1.8m (31 December 2019: £2.1m) and had cash of £1.7m as at 14 April 2020 and no debt.

 

Bioplastics Division

 

Revenues in the Bioplastics division of £1.1m were up 83% on the same period last year and matched the record quarterly revenues of Q4 2019 (Q1 2019: £0.6m; Q4 2019: £1.1m). The performance in the period was underpinned by increased sales of outer packaging for the US single serve coffee market and by growing revenues for rigid ring materials for the coffee-pod market. There is growing evidence that the ordering of coffee products for home delivery was supporting demand towards the end of the quarter. Progress on other projects, such as the nutraceutical pod, was more limited as Covid-19 began to impact some customers' developmental activities. For others, developmental work continues with some vigour and the business is well positioned to exploit various opportunities in this growing market as and when conditions allow.

 

Stanelco RF Technologies Division

 

Revenues for the first quarter of 2020 in the Stanelco RF division were £0.2m (Q1 2019: £1.5m). The Stanelco RF division's principal revenues are derived from the production and maintenance of furnaces for the manufacture of fibre optical cable. Market intelligence currently indicates that there is over capacity in the fibre optic cable market. This market position is now exacerbated by the effect of Covid-19 on sentiment towards purchases of capital goods. It is unlikely that this position will change quickly and the Group's expectations are already set accordingly. The Board expects demand for fibre optic cable for internet capacity and 5G implementation to recover in due course. At present the division's sales activities are focused on alternative industrial markets in the UK/Europe which the Board believes will support increased revenues in the second half of 2020.

 

Other matters

 

In Biome's announcement on 25 March 2020, it was stated that the Company's AGM had been deferred to a date in June 2020 due to the Covid-19 crisis. A further announcement will be made when the precise date when the AGM will be held can be confirmed.

 

Outlook

 

The Group's trading continues in line with the expectations set out in the Company's Final Result's announcement released on 16 April 2020.

 

The Final Results announcement also outlined the range of actions the Board is taking as a result of Covid-19. The focus of these actions is to maximise Biome's commercial opportunities whilst managing the Group's cost base and cash resources with the aim of delivering good medium-term growth for shareholders.

 

 

 

 

- Ends -

 

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

David Hughes, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKDBBOBKDKQB
Date   Source Headline
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.